• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ANR
Click for more information
0.00% 7.0¢

ANATARA LIFESCIENCES LTD - Corporate Spotlight

Market Cap $13.50M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is... Anatara Lifesciences Ltd is an Australia-based life sciences company. The Company is engaged in developing evidence-based solutions for gastrointestinal diseases in humans and animals. Its products include Gastrointestinal ReProgramming (GaRP), Detach, BONIFF, and ANR-pf. Its GaRP Product is a microbiome-targeted multi-component complementary medicine, which is designed to address the primary underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Detach is a non-antibiotic approach to aid in the control of diarrheal disease known as scour, which is developed using bromelain. BONIFF is a revised formulation which is applied to dry feed for piglets after weaning, reducing labor input, and simplifying the entire process. ANR-pf is an enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

(20min delay)
Last
7.0¢ 		Change
0.000(0.00%) 		Mkt cap ! $13.50M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
2 124555 6.4¢
 

Sellers (Offers)

Price($) Vol. No.
6.8¢ 309 1
View Market Depth
Last trade - 16.04pm 02/10/2024 (20 minute delay) ?
Last
6.9¢ 		  Change
0.000 ( 0.00 %)
Open High Low Volume
6.9¢ 6.9¢ 6.9¢ 1285
Last updated 14.18pm 02/10/2024 ?
ANR (ASX) Chart

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.